FOXO1 (Forkhead box O1)

Our findings indicate that periplogenin suppresses hepatocarcinogenesis by inducing cellular senescence through activation of the FOXO1/P53 pathway. These results highlight the potential of periplogenin as a novel therapeutic agent for the treatment of hepatocellular carcinoma.

This review highlights a need for further research of the TME in each fusion subtype. This will improve our understanding of how the fusion gene drives malignancy and ultimately aids in the development of novel treatment strategies.

Their structures were elucidated using 1D and 2D NMR experiments and their absolute configurations determined using semisynthetic and electronic circular dichroism methods. The gonystylones were found to be cytotoxic to rhabdomyosarcoma cells at low micromolar concentrations (3-19 μM).

P3, N=118, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2026 | Trial primary completion date: Sep 2027 --> Jun 2026

Despite overall excellent survival rates, challenges remain in reducing long-term morbidity and personalising treatment through genetic and molecular knowledge. This review offers current recommendations and highlights the importance of a multi-disciplinary approach in the diagnosis, staging and treatment of orbital RMS.

In summary, we report 7 new BRAF fusions in PTC BRAF V600E-WT. Additional clinical research is needed to elucidate the behavior of BRAF fusion-driven thyroid carcinomas and the therapeutic utility of MAPK pathway inhibitors.

Farnesyltransferase (FTase) inhibitors (FTIs), such as tipifarnib, inhibit HRAS membrane localization and blunt RAS effector signaling, leading to an antitumor effect in HRAS-mutant FN-RMS preclinical models...Co-targeting FTase and MEK restrained tumor progression and induced terminal myogenic differentiation. These findings highlight an effective combinatorial strategy and support its preclinical translation for patients with HRAS-mutant RMS.

The findings indicated that DHA could impede the development of liver cancer through FoxO1 regulation, suggesting that targeting FoxO1 may represent a promising therapeutic approach for liver cancer treatment.

Finally, the expression pattern of FOXO1 in HCC and its association with tumour proliferation ability were verified through basic experiments. FOXO1 was identified to regulate the immune microenvironment and the tumour proliferation ability in HCC, demonstrating its potential as a therapeutic target for HCC.

The results presented in this study indicate that FOXO1 has a tumor suppressor function, while FADD has a tumor-promoting function in OS following anticancer drug treatment. The experimental approach used in this investigation also indicates that FADD antagonizes the effect of FOXO1 on p21 expression in OS.

Cancer chemotherapy mainly vincristine, dactinomycin, and cyclophosphamide, surgery, radiotherapy, and brachytherapy were the common keywords of treatment. The more common keywords such as age, facial neoplasms, mouth neoplasms, orbital neoplasms, gingiva, mandible, DNA-binding proteins, gene silencing, and Rh30 cell line were reported by stomatologists. This study is the first comprehensive report of the scientometric characteristics of RMS publications by pediatricians and stomatologists, highlighting the need for increased awareness among clinicians to avoid diagnostic delays and ensure timely treatment.

Targeted therapy that tailors treatment plans to the individual patient may provide additional benefits for RMS patients. This review describes the frequent genetic mutations observed in RMS patients and drug development based on these mutations shall provide direction to develop targeted therapy leading to effective personalized treatment for RMS patients.